Anna K Russell

US Patent:

6670167, Dec 30, 2003

Filed:

Dec 14, 1999

Appl. No.:

09/460421

Inventors:

Ping Chen - San Diego CA
Mark Anderson - San Diego CA
Ya-Li Deng - San Diego CA
Smita Gaur - San Diego CA
Chen Chen Kan - Arcadia CA
Chun Luo - San Diego CA
Karen Lundgren - San Diego CA
Stephen Margosiak - Escondido CA
Binh Nguyen - San Diego CA
Patrick OConnor - San Diego CA
James Register - San Diego CA
Anna Tempczyk Russell - San Diego CA
Jay Sarup - San Diego CA

Assignee:

Agouron Pharmaceuticals, Inc. - San Diego CA

International Classification:

C07H 2104

US Classification:

43525233, 4352351, 435348, 43525411, 4352523, 435419, 435325, 4353201, 536 232, 536 235

Abstract:

The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1. 7 crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.

US Patent:

7285562, Oct 23, 2007

Filed:

Jul 28, 2004

Appl. No.:

10/900957

Inventors:

Mark D. Kafka - San Diego CA, US
Mark E. Wilson - Ramona CA, US
Anna Russell - Ramona CA, US
Gary D. Lopaschuk - Edmonton, CA
Jason R. Dyck - Sherwood Park, CA

Assignee:

Chugai Seiyaku Kabushiki Kaisha - Tokyo

International Classification:

A61K 31/44
A61K 31/425
A61K 31/415

US Classification:

514301, 514302, 514367, 514387

Abstract:

The present invention provides methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.

US Patent:

7897615, Mar 1, 2011

Filed:

Oct 2, 2007

Appl. No.:

11/866266

Inventors:

Mark D. Kafka - San Diego CA, US
Mark E. Wilson - Ramona CA, US
Anna Russell - Ramona CA, US
Gary D. Lopaschuk - Edmonton, CA
Jason R. Dyck - Sherwood Park, CA

Assignee:

Chugai Sciyaku Kabushiki Kaisha - Tokyo

International Classification:

A61K 31/44
A61K 31/41
A61K 31/425
A61K 31/42

US Classification:

514301, 514302, 514361, 514367, 514376

Abstract:

The present invention provides previous methods for the use of compounds as depicted by structure I, pharmaceutical compositions containing the same, and methods for the prophylaxis, management and treatment of metabolic diseases and diseases modulated by MCD inhibition. The compounds disclosed in this invention are useful for the prophylaxis, management and treatment of diseases involving in malonyl-CoA regulated glucose/fatty acid metabolism pathway. In particular, these compounds and pharmaceutical composition containing the same are indicated in the prophylaxis, management and treatment of cardiovascular diseases, diabetes, cancer and obesity.

US Patent:

20030235899, Dec 25, 2003

Filed:

Jan 28, 2003

Appl. No.:

10/353274

Inventors:

Ping Chen - San Diego CA, US
Mark Anderson - San Diego CA, US
Ya-Li Deng - San Diego CA, US
Smita Gaur - San Diego CA, US
Chen Kan - Arcadia CA, US
Chun Luo - San Diego CA, US
Karen Lundgren - San Diego CA, US
Stephen Margosiak - Escondido CA, US
Binh Nguyen - San Diego CA, US
Patrick O'Connor - San Diego CA, US
James Reqister - San Diego CA, US
Anna Russell - San Diego CA, US
Jay Sarup - San Diego CA, US

International Classification:

C12P021/02
C07H021/04
C12N009/12
C12N005/06

US Classification:

435/194000, 435/069100, 435/320100, 435/325000, 536/023200

Abstract:

The present invention relates to the identification, isolation and purification of the catalytic domain of the human effector checkpoint protein kinase (hChk1). A 1.7 crystal structure of the hChk1 kinase domain in the active conformation is reported herein. The kinase domain of hChk1 and its associated crystal structure is described for use in the discovery, identification and characterization of inhibitors of hChk1. This structure provides a three-dimensional description of the binding site of the hChk1 for structure-based design of small molecule inhibitors thereof as therapeutic agents. Inhibitors of hChk1 find utility in the treatment of hyperproliferative disorders such as HIV and cancer.

US Patent:

20060025474, Feb 2, 2006

Filed:

Mar 8, 2005

Appl. No.:

11/076584

Inventors:

David Wallace - San Diego CA, US
Thomas Arrhenius - Del Mar CA, US
Anna Russell - San Diego CA, US
Dingguo Liu - San Marcos CA, US
Amy Xing - San Diego CA, US
Sovouthy Tith - Phoenix AZ, US
Zheng Hou - San Diego CA, US
Tadakatsu Takahashi - Shizuoka, JP
Yoshiyuki Ono - Shizuoka, JP
Hirotaka Kashiwagi - Shizuoka, JP
Kazuki Shimizu - Shizuoka, JP
Hitoshi Ikura - Kanagawa, JP

International Classification:

A61K 31/366
A61K 31/365
A61K 31/192

US Classification:

514460000, 514568000, 514474000, 549295000, 562466000

Abstract:

The present invention discloses bisphenyl compounds of the formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W are defined herein after. These compounds are useful as pharmaceuticals.